Welcome to Stemline Therapeutics US Medical
This site is intended for healthcare professionals licensed in the United States and is for nonpromotional informational purposes only. Please verify that you are a licensed healthcare professional to find out more about Stemline Therapeutics US Medical Online.
- I am a US healthcare professional
- I am a US population health decision maker
- I am an ex-US healthcare professional
- I am not a healthcare professional
You are now leaving Stemline Therapeutics US Medical. Stemline Therapeutics, Inc. does not review the information contained on the following website for content, accuracy, or completeness. Use of and access to the information is subject to the terms, limitations, and conditions set by the website producer. Stemline Therapeutics, Inc. makes no claims about the accuracy or any other aspect of the information contained on this website, nor does Stemline Therapeutics, Inc. endorse the following website.
The email address is already in use
- Vendor Contacts
- Request Tagraxofusp Starter Kit
- Questions can be triaged based on keywords to send to right MRD
- Set up a meeting with a local MSL
- Ordering Information
- Quick Links to open access articles and presentations
- Access to Cerner and Epic Order Sets
- Access to TAG centers of excellence
- Request a safety meeting
As a part of our mission to develop innovative oncology and hematology therapeutics for patients with cancer, Stemline acknowledges the important role of partnering with the community to support ongoing medical education. Stemline expects that all requests have a compelling rationale, supported by available data, with the potential to enhance the understanding of our medicines, deliver innovative therapies to patients, address unmet medical needs, and improve patient care. All proposed activities will align with our priorities and maintain the privacy rights, safety, and the welfare of patients. To submit a proposal, visit our submission portal for further instructions.
Menarini Stemline supports independent and collaborative Medical Research
As a part of our mission to develop innovative therapeutics for patients with unmet need, Menarini Stemline acknowledges the important role of partnering with the medical and scientific community to conduct ethical and impactful independent and collaborative medical research. We can support Independent and Collaborative Research through the provision of drug(s), funding, supplies, and/or in-kind services.
Independent Scientific Research: Research that is initiated, planned, and conducted by an independent external researcher or sponsor. Menarini Stemline does not take any regulatory or legal responsibility for the study or assist with research activities. Known throughout our industry as Investigator Sponsored Research, Investigator Initiated Trials, Investigator Sponsored Studies, etc.
Collaborative Scientific Research: Research that is initiated, planned and conducted by an external researcher or sponsor. Menarini Stemline may assist with one or more research activities, which will be dependent on the project.
Menarini Stemline expects that all requests contain a compelling rationale, supported by available data, with the potential to enhance the understanding of our medicines, deliver innovative therapies to patients, address unmet medical needs, and improve patient care. We employ a careful, cross functional evaluation of the scientific merit and strategic relevance of each request we receive. When proposed research is expected to take place in humans, the privacy rights, safety, and the welfare of patients are paramount
Our program accepts requests for the following types of Medical Research:
- Non-Interventional Research (i.e., Real World Evidence, Observational, and/or Health Outcomes and Economics Research): Research utilizing data collected in either a prospective or retrospective manner, of the observation of clinical practices and/or patient reported experiences
Menarini Stemline supports independent and collaborative Medical Research
As a part of our mission to develop innovative therapeutics for patients with unmet need, Menarini Stemline acknowledges the important role of partnering with the medical and scientific community to conduct ethical and impactful independent and collaborative medical research. We can support Independent and Collaborative Research through the provision of drug(s), funding, supplies, and/or in-kind services.
Independent Scientific Research: Research that is initiated, planned, and conducted by an independent external researcher or sponsor. Menarini Stemline does not take any regulatory or legal responsibility for the study or assist with research activities. Known throughout our industry as Investigator Sponsored Research, Investigator Initiated Trials, Investigator Sponsored Studies, etc.
Collaborative Scientific Research: Research that is initiated, planned and conducted by an external researcher or sponsor. Menarini Stemline may assist with one or more research activities, which will be dependent on the project.
Menarini Stemline expects that all requests contain a compelling rationale, supported by available data, with the potential to enhance the understanding of our medicines, deliver innovative therapies to patients, address unmet medical needs, and improve patient care. We employ a careful, cross functional evaluation of the scientific merit and strategic relevance of each request we receive. When proposed research is expected to take place in humans, the privacy rights, safety, and the welfare of patients are paramount.
Our program accepts requests for the following types of Medical Research:
- Interventional Research (Phases I-IV): Clinical research involving one or more of Menarini Stemline’s products
As a part of our mission to develop innovative oncology and hematology therapeutics for patients with cancer, Stemline acknowledges the important role of partnering with the community to support patient advocacy activities. Stemline expects that all requests have a compelling rationale, supported by available data, with the potential to enhance the understanding of our medicines, deliver innovative therapies to patients, address unmet medical needs, and improve patient care. All proposed activities will align with our priorities and maintain the privacy rights, safety, and the welfare of patients. To submit a proposal, visit our submission portal for further instructions.
As a part of our mission to develop innovative oncology and hematology therapeutics for patients with cancer, Stemline acknowledges the important role of partnering with the community to support ongoing medical education. Stemline expects that all requests have a compelling rationale, supported by available data, with potential to enhance the understanding of our medicines, deliver innovative therapies to patients, address unmet medical needs, and improve patient care. All proposed activities will align with our priorities and maintain the privacy rights, safety, and the welfare of patients.
Our program accepts requests for the following types of proposals. Please submit proposals to grants@menarinistemline.com. The team will review and respond to proposals in a timely manner.
- Medical Education Grants
As a part of our mission to develop innovative oncology and hematology therapeutics for patients with cancer, Stemline acknowledges the important role of partnering with the community to support third party sponsorships, patient advocacy activities and charitable donations. Stemline expects that all requests have a compelling rationale, supported by available data, with potential to enhance the understanding of our medicines, deliver innovative therapies to patients, address unmet medical needs, and improve patient care. All proposed activities will align with our priorities and maintain the privacy rights, safety, and the welfare of patients.
Our program accepts requests for the following types of proposals. Please submit proposals to grants@menarinistemline.com.The team will review and respond to proposals in a timely manner.
- Third Party Sponsorships & Events
- Patient Advocacy Support
- Charitable Grants & Donations
As a part of our mission to develop innovative oncology therapeutics for patients with cancer, Stemline acknowledges the important role of partnering with the scientific community to conduct ethical independent and collaborative research. Stemline considers external requests for study drug, a financial contribution, and/or other requested support for the conduct of such studies. Stemline’s global and regional cross functional teams evaluate the scientific merit and strategic relevance of each submission carefully.
Stemline expects that all requests have a compelling rationale, supported by available data, with potential to enhance the understanding of our medicines, deliver innovative therapies to patients, address unmet medical needs, and improve patient care. When proposed research is expected to take place in humans, the privacy rights, safety, and the welfare of patients is paramount.
Our program accepts requests for the following study types:
- Interventional Clinical Research (Phases I-IV): Clinical research involving one or more of Stemline’s products
- Observational Research (i.e. Real-World Evidence or Health Outcomes and Economics Research): Research utilizing data collected in either a prospective or retrospective manner, of the observation of clinical practices and/or patient reported experiences
Your have successfully logged out. Thank you.
We are processing your registration.
Bookmark Stemline product resources for future reference by clicking the icon.
Please login to access this feature.Unable to process your request please try later.
This content is intended for personal, educational purposes only. You may not reproduce or distribute without permission from Stemline Therapeutics. If you would like a copy, please contact Stemline Therapeutics Medical Information at 1-877-332-7961. Please refer to the full Prescribing Information.
Contact Stemline Therapeutics US Medical Information
Please select your preferred method of connection:
Please contact our dedicated medical information hotline at 1-877-332-7961.
Our team is available during regular business hours, Monday through Friday, from 8:30 am to 5:30 pm EST.
During U.S. holidays and weekends, responses may be delayed.
Helps organize and store your bookmarks long term. You could use them to read later. As you bookmark documents by clicking the icon, they will appear here.
Find my MSL
Select a Product*
- ORSERDU® (elacestrant)
- ELZONRIS® (tagraxofusp-erzs)
- Pipeline/Investigational products

Alina, PharmD, BCOP, BCPS
Login
Create an account? SIGN UP
Email Verification
Enter OTP
Reset Password
Proposed Mechanism of Action
NA
Additional Detail
NA
Proposed Mechanism of Action
SERD (ER)
Additional Detail
ELCIN Trial is an open-label multicenter Ph 2 trials of Elacestrant in women and men with CDK4/6 inhibitor naïve ER+/HER2- metastatic breast cancer. The study investigates elacestrant as single agent without prior CDK4/6i exposure.
Proposed Mechanism of Action
SERD (ER)
Additional Detail
ELECTRA Trial is An Open-label Multicenter Phase 1b/2 Study of Elacestrant in Combination with Abemaciclib in Women and Men with Brain Metastasis from Estrogen Receptor positive, HER-2 Negative Breast Cancer. ELECTRA is a Global Study with the aim of determining the activity of elacestrant in combination with Abemaciclib in BC EH+/HER2- with brain metastases.
Proposed Mechanism of Action
SERD (ER)
Additional Detail
ELEVATE Trial is A Phase 1b/2, Open-Label Umbrella Study to Evaluate Safety and Efficacy of Elacestrant in various combination in patients with ER+/HER2- metastatic Breast Cancer. ELEVATE is a Global Study which the aim of determining safety and efficacy of combining elacestrant with other agents in the metastatic setting.
Proposed Mechanism of Action
Targeted Biologic (CD123)
Additional Detail
TAGRAXOFUSP is a novel targeted therapy directed to the IL-3 receptor α (CD123), a target present on a wide range of malignancies including Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). It comprises human IL-3 recombinantly fused to a truncated diphtheria toxin (DT) payload engineered such that IL-3 replaces the native DT receptor-binding domain. The IL-3 domain of TAGRAXOFUSP directs the cytotoxic DT payload to cells expressing CD123. Upon internalization, TAGRAXOFUSP irreversibly inhibits protein synthesis and induces apoptosis of the target cell. TAGRAXOFUSP was approved by the U.S. FDA in 2018 for the treatment of adult and pediatric patients, 2 years or older, with BPDCN.
Indication
BPDCN
Proposed Mechanism of Action
Targeted Biologic (CD123)
Additional Detail
ELZONRIS was approved by the EMA in 2021 as monotherapy for the first-line treatment of adult patients with BPDCN.
Education on ELZONRIS
Request a safety meeting with your local MSL
PLAN Brochure
TAG Safety Deck
Equipment
Administration Components and Vendor Contacts
Publications and Presentations
Quick links to open access articles and presentations
Questions on ELZONRIS?
Search the ELZONRIS repository of product information and medical letters
"Request a meeting with an MSL" or "Submit an Inquiry to Medical Information"
Formulary Review Materials (This information is intended for population health decision makers)
Request a meeting with a member of our clinical value and evidence teams
List of required components for dose preparation and administration

According to the full prescribing information, the following materials are required for the administration of tagraxofusp:
Syringe pump: B. Braun Perfusor (product number: 8713030U)
Y-connector: Smith’s Medical Mini Bifuse (product number: MBF27)
Filter: Pall Supor AEF Intravenous Filter Set (product number: AEF1E)
Tubing: Baxter Micro-Volume Extension Set, 60” (product number: 2N3348)
Administration supplies may be available from the following suppliers using the product numbers listed above:
McKesson Medical Surgical (855) 571-2100
ASD Healthcare (800) 746-6273
Fisher Scientific (800) 766-7000: Y-Connector (product number: NC1286822)
Medical grade freezer and syringe pump may be available from the following suppliers using the contact information and product numbers listed here:
Medicapital Rent (888) 663-2105: 1.5 cu. ft. 70 liter, standard medical grade freezer, temp range -20°C (product number: FV20-70)
Medical Device Depot (877) 646-3300: 1.5 cu. ft. 70 liter, ABS standard undercounter medical freezer, temp range -20°C (product number: ABT-HC-UCFS-0220M)
Additional syringe pump suppliers: ASD (800) 746-6273, McKesson (855) 571-2100, and Agiliti (800) 847-7368
Did not find what you were looking for?
Please fill out a medical information request form with your specific question
Miami Breast Cancer Conference® (MBCC)
Posters
Elacestrant vs standard-of-care in ER+/HER2- advanced or metastatic breast cancer (mBC) with ESR1 mutation: Key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
Product: Orserdu
Bardia A, Shaughnessy JO, Bidard FC, et al
Miami Breast Cancer Conference® (MBCC) March 2024
Poster 10
EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy
Product: Orserdu
Cortes J, Bidard FC, Bardia A, et al
Miami Breast Cancer Conference® (MBCC) March 2024
Poster 14
ELECTRA: An open-label, multicenter, phase 1b/2 study of elacestrant in combination with abemaciclib in patients with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer (BC)
Product: Orserdu
Ibrahim N, Kim SB, Lin NU, et al
Miami Breast Cancer Conference® (MBCC) March 2024
Poster 25
ELEVATE: A phase 1b/2, open-label, umbrella study evaluating elacestrant in various combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC)
Product: Orserdu
Rugo HS, Bardia A, Hamilton E, et al
Miami Breast Cancer Conference® (MBCC) March 2024
Poster 32
Estimating the direct and indirect resource burden of treatment management with current standard of care or elacestrant for ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer patients: A population-level provider model
Product: Orserdu
Vidal GA, Cinfio F, Badaracco J, et al
Miami Breast Cancer Conference® (MBCC) March 2024
Poster 40
Miami Breast Cancer Conference® (MBCC)
Posters
Elacestrant, an oral selective estrogen receptor degrader (SERD), vs investigator’s choice of endocrine monotherapy for ER+/HER2- advanced/metastatic breast cancer (mBC) following progression on prior endocrine and CDK4/6 inhibitor therapy: Results of EMERALD phase 3 trial
Product: Orserdu
Bardia A, Neven P, Montero AJ, et al
Miami Breast Cancer Conference® (MBCC) March 2022
Poster
American Association for Cancer Research® (AACR)
Posters
Efficacy of novel oral SERD elacestrant in fulvestrant-refractory hormone receptor-positive (HR+) breast cancer: A translational investigation
Product: Orserdu
Dubash TD, Bardia A, Chirn B, et al
American Association for Cancer Research® (AACR) April 2023
Poster CT073
Assistance ?
Looking for more information?
-
Contact Stemline Therapeutics US
Medical Information -
Submit Medical Inquiry
-
Schedule a Virtual Meeting
Please contact our dedicated medical information hotline at 1-877-332-7961.
Our team is available during regular business hours, Monday through Friday, from 8:30 am to 5:30 pm EST.
During U.S. holidays and weekends, responses may be delayed.
Publication Alert: A new elacestrant article has been published in Clinical Cancer Research. Please click here to view more detail
✕
Stemline Therapeutics US Medical
Provides comprehensive product and disease state information when, where and how it is needed. This information can be provided in the following manner:
Personal Digital Briefcase
Information and materials are available that can be viewed, downloaded and saved. This information is found under Product Information, Disease State Information, Pipeline and Clinical Trials and Population Health & Real-World Resources.
The scientific information provided on this website may include data/information on investigational use(s) of compounds/drugs for which efficacy and safety have not been established. Information available on this website is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Menarini-Stemline products.

Find my Medical Science Liaison (MSL)
Connect with a local Stemline expert.


Report an Adverse Event/ Product Quality Complaint
Stemline Therapeutics prioritizes patient safety. Please use one of the following methods to report adverse events or product complaints.
To report, call 1-877-332-7961 or click here.
The information on this site is offered exclusively for general educational purposes. It is advisable to use independent judgment before applying any information to your specific practice requirements. Third-party information presented reflects the writers' perspectives and not the stance of Stemline.